Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
3/30/2023
Central Government Issues the Notice on Further Facilitating Medical E...
3/30/2023
Boehringer Ingelheim Remains Confident of Its China Prospects Despite ...
3/30/2023
Rxilient and Junshi form JV to Develop and Commercialize Toripalimab i...
3/29/2023
JPO Publicizes 8th VBP Tender Outcome, Which Cuts Average Price by 56%
3/29/2023
Investing in China's Healthcare Sector (China Briefing)
3/28/2023
Uptake of Hepatitis C Direct-Acting Antiviral Treatment in China: A Re...
3/28/2023
CDE Issues the Technical Guidelines for the Application of Physiologic...
3/28/2023
NHSA Issues the NHSA Notice on Improving the Price Formation Mechanism...
3/28/2023
Chinese Scientists Develop New Vaccine Strategy by Entrapping Live Vir...
3/27/2023
BioNTech and Oncoc4 Sign Strategic Collaboration for Novel Checkpoint ...
3/27/2023
NCC: China's Tumor Registration System Covers 1.407B Population
3/27/2023
AstraZeneca to Further Expand R&D Presence in China
3/27/2023
Hepalink's OncoVent Enter License Deal with Orient EuroPharma for Oreg...
3/24/2023
InvoX Pharma's F-star Announces 2nd Licence Deal with Takeda
3/24/2023
Brii Bio Drops Once-promising COVID Cocktail for Variants
3/24/2023
AstraZeneca's Blood Cancer Drug Calquence Gets Conditional Approval in...
3/24/2023
NMPA Publishes the 2022 Annual Report for Adverse Drug Reaction Monito...
3/24/2023
NMPA Issues the Procedures for Adjustment of Published Reference Formu...
3/24/2023
CDE Issues the "Common Pharmacy Issues and Related Technical Requireme...
3/24/2023
CDE Issues the Technical Guidelines for Clinical Research and Developm...
3/24/2023
Pfizer Signs MOU with HCRC Aimed at Improving Rural Health in China
3/24/2023
New Report: Incidence of Moderate and Severe Ovarian Hyperstimulation ...
3/24/2023
Drug R&D and Product Registration News Digest March 2023 (4)
3/24/2023
U.S.-China Collaboration Could Cut Development Time, Cost For New Canc...
3/23/2023
Roche, CR Pharma Tie Up to Improve Access of Flu Drug Xofluza in Chna
3/23/2023
Chinese Government Issues the Opinions for Further Improving Healthcar...
3/23/2023
CDE Solicits Comments on the Dossier Requirements for Marketing Regist...
3/22/2023
Biohaven Licenses ex-China Rights of Highlightll Pharma's TYK2/JAK1 Du...
3/22/2023
NMPA Issues Announcement for Applicability of ICH Guidelines S1B(R1)/Q...
3/22/2023
CDE Solicits Comments on the Technical Guidelines for Virus Removal/In...
Page:
123
/
790
Total number of articles:
23688
:
[First]
[<<]
[121]
[122]
[123]
[124]
[125]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit